Antithrombotic strategies for patients with peripheral artery disease
Selected in JACC Scientific Statement by Xavier Devoisin
Patients with peripheral artery disease (PAD) face significant cardiovascular and limb risks, requiring tailored antithrombotic strategies balancing efficacy and bleeding risk. A multidisciplinary work group reviewed current evidence, highlighted differences in treatment responses between PAD and coronary artery disease, and provided guidance on clinical decision-making and future research directions.
References:
Authors: Marc P. Bonaca, Geoffrey D. Barnes, Rupert Bauersachs, Youssef Bessada, Michael S. Conte, Anahita Dua, Connie N. Hess, Maya Serhal, Carlos Mena-Hurtado, Jeffrey I. Weitz, and Joshua A. Beckman
Reference: JACC. 2024 Sep, 84 (10) 936–952
DOI: doi/10.1016/j.jacc.2024.06.027
Read the abstractObjective:
The objective is to define an antithrombotic treatment strategy for patients with distal arterial disease after revascularisation.
Study:
Literature review on antithrombotic strategies for preventing cardiovascular and lower limb events in patients with distal arterial disease, supplemented by the analysis of typical clinical cases.
Endpoint:
The primary endpoint was mainly MACE (view tables below for more details).
Outcomes and conclusion:
Limited data is available on the effectiveness of antithrombotic therapies following revascularisation in patients with distal arterial disease.
Two studies (VOYAGER and COMPASS) support the routine use of a combination of low-dose aspirin and rivaroxaban after revascularisation.
Comments:
Key Consideration:
The importance of addressing cardiovascular risk factors in parallel with antithrombotic strategies.